###begin article-title 0
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
###end article-title 0
###begin p 1
###xml 664 665 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 676 680 670 674 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 855 856 845 846 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 439 447 <span type="species:ncbi:9606">patients</span>
###xml 954 959 <span type="species:ncbi:9606">human</span>
###xml 1252 1260 <span type="species:ncbi:9606">patients</span>
Macrophages (Mphi) are prominent components of solid tumors and exhibit distinct phenotypes in different microenvironments. We have recently found that tumors can alter the normal developmental process of Mphi to trigger transient activation of monocytes in peritumoral stroma. We showed that a fraction of monocytes/Mphi in peritumoral stroma, but not in cancer nests, expresses surface PD-L1 (also termed B7-H1) molecules in tumors from patients with hepatocellular carcinoma (HCC). Monocytes activated by tumors strongly express PD-L1 proteins with kinetics similar to their activation status, and significant correlations were found between the levels of PD-L1+ and HLA-DRhigh on tumor-infiltrating monocytes. Autocrine tumor necrosis factor alpha and interleukin 10 released from activated monocytes stimulated monocyte expression of PD-L1. The PD-L1+ monocytes effectively suppressed tumor-specific T cell immunity and contributed to the growth of human tumors in vivo; the effect could be reversed by blocking PD-L1 on those monocytes. Moreover, we found that PD-L1 expression on tumor-infiltrating monocytes increased with disease progression, and the intensity of the protein was associated with high mortality and reduced survival in the HCC patients. Thus, expression of PD-L1 on activated monocytes/Mphi may represent a novel mechanism that links the proinflammatory response to immune tolerance in the tumor milieu.
###end p 1
###begin p 2
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 298 299 298 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 704 705 704 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
Tumor progression is now recognized as the product of evolving cross talk between different cell types within the tumor and its stroma (1, 2). Although normal stroma is nonpermissive for neoplastic progression, cancer cells can modulate adjacent stroma to generate a supportive microenvironment (1-3). This includes the ability to alter the ratios of effector to regulatory T cells and to affect the functions of APCs and the expression of cosignaling molecules, which in turn creates an immunosuppressive network to promote tumor progression and immune evasion (3, 4). There is also emerging evidence that the proinflammatory response at the tumor stroma can be rerouted in a tumor-promoting direction (5). These observations suggest that different tumor microenvironments can create either immune suppression or activation at distinct sites to promote tumor progression.
###end p 2
###begin p 3
###xml 295 296 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 297 298 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 484 485 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 561 562 557 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 638 642 632 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 646 647 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
Macrophages (Mphi) constitute a major component of the leukocyte infiltrate in tumor stroma. These cells are derived almost entirely from circulating monocytes, and in response to environmental signals, they acquire special phenotypic characteristics that are associated with diverse functions (6-8). We have recently found that tumor environments can alter the normal development of Mphi that is intended to trigger transient early activation of monocytes in the peritumoral region (7). Furthermore, in a study of patients with hepatocellular carcinoma (HCC) (5), it was noted that an increased number of activated monocytes/Mphi (HLA-DRhighCD68+ cells) in the liver was associated with progression of the disease. Thus, immune functional data of activated monocytes/Mphi in cancer environments are essential for understanding their roles and potential mechanisms in tumor immunopathogenesis.
###end p 3
###begin p 4
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 597 598 593 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 603 605 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 803 804 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 806 808 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 678 683 <span type="species:ncbi:10090">mouse</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 938 943 <span type="species:ncbi:9606">human</span>
PD-L1 (also termed B7-H1 and CD274) is a member of the B7 family of cosignaling molecules, and it possesses the dual functions of co-stimulation of naive T cells via an as yet unidentified receptor and coinhibition of activated effector T cells through PD-1 receptor (4, 9, 10). Expression of PD-L1 (B7-H1) is often induced or maintained by many inflammatory cytokines (4, 11), of which IFN-gamma is the most potent. In addition to being expressed on activated immune cells, most human cancers also express high levels of PD-L1 (B7-H1) protein, which correlates with poor prognosis in some cases (4, 11-13). In contrast, low or rare PD-L1 (B7-H1) expression is observed in most mouse and human tumor cell lines, possibly because of the lack of a complete cancer microenvironment in cell lines in vitro (4, 12). At present, little is known about the expression and function of PD-L1 (B7-H1) on APCs in the inflammatory activated stroma of human tumors in situ.
###end p 4
###begin p 5
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 153 154 153 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 437 438 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
HCC is the fifth most common cancer worldwide, with an extremely poor prognosis (14). By using HCC as a model system, the present study showed that PD-L1+ monocytes were accumulated in the peritumoral stroma area of cancers and increased with tumor progression. The pattern of PD-L1 (B7-H1) expression coincided with the transient activation of monocytes/Mphi during their initial exposure to the tumor environment. These activated PD-L1+ monocytes suppressed tumor-specific T cell immunity, and their high infiltration was associated with poor survival of the HCC patients. Moreover, we found that blocking PD-L1 (B7-H1) effectively attenuated this monocyte-mediated T cell anergy and restored their antitumor activity in vivo. Therefore, PD-L1 (B7-H1) expression on activated monocytes may represent a novel mechanism by which the proinflammatory response is linked to immune tolerance in the tumor milieu.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
PD-L1+ monocytes are highly enriched in the peritumoral stroma of HCC patients
###end title 7
###begin p 8
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 380 381 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 402 406 400 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 583 584 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 846 847 844 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 851 855 849 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 932 943 930 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A&#8211;C</xref>
###xml 989 990 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 994 998 992 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1113 1114 1111 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1166 1167 1164 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1229 1244 1227 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, A and B</xref>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 266 274 <span type="species:ncbi:9606">patients</span>
###xml 541 549 <span type="species:ncbi:9606">patients</span>
###xml 1084 1092 <span type="species:ncbi:9606">patients</span>
To evaluate the potential role of PD-L1 in tumor immunopathology, we examined surface expression of this protein on circulating leukocytes from HCC patients and healthy donors, and on infiltrating leukocytes freshly isolated from tumor and nontumor liver tissues of patients with various stages of HCC (n = 28 in each group). In all of the samples analyzed, 92 +/- 7% of the PD-L1+ leukocytes were CD14high cells that were considered as monocytes. PD-L1 was weakly expressed on a fraction of circulating monocytes in both healthy donors and patients. Although the percentage of PD-L1+ cells was increased in nontumor-infiltrating monocytes, their intensity of PD-L1 expression was low. Compared with nontumor-infiltrating monocytes, the monocytes isolated from the corresponding tumor tissues comprised a significantly greater proportion of PD-L1+CD14high cells and expressed significantly larger amounts of PD-L1 (both P < 0.0001; Fig. 1, A-C). Moreover, we found that the ratios of PD-L1+CD14high cells in both nontumor and tumor-derived monocytes were higher in advanced stage HCC patients (stages III and IV; n = 13) than those in early stages (stages I and II; n = 15; P < 0.05 for nontumor and P < 0.001 for tumor tissues; Fig. 1, A and B).
###end p 8
###begin p 9
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Monocytes isolated from human HCC tumor tissue expressed PD-L1.</bold>
###xml 190 191 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 195 199 195 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 275 279 275 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
Monocytes isolated from human HCC tumor tissue expressed PD-L1. (A-C) FACS analysis of PD-L1 expression on fresh monocytes isolated from peripheral blood and tissues. The percentage of PD-L1+CD14high monocytes (A and B) and the mean fluorescence intensity (MFI) of PD-L1+CD14high cells (C) are shown. The numbers of samples collected from patients and donors in A-C were as follows: blood from 28 healthy individuals, and 21 stage I and II and 7 stage III and IV HCC patients; and paired nontumor and tumor tissue from 15 stage I and II and 13 stage III and IV HCC patients. The data shown in A are representative dot plots of at least seven individuals from more than five independent experiments; B and C show the statistical analysis of these samples. The continuous and dashed horizontal bars in B represent median values. Results are expressed as means +/- SEM. (D) Analysis of PD-L1 distribution in HCC samples by confocal microscopy. The micrographs at higher magnification show the stained peritumoral stroma region (1) and a cancer nest (2). Significant difference compared with healthy blood is indicated (***, P < 0.0001). 1 out of 10 representative micrographs is shown in D. Bar, 50 microm.
###end p 9
###begin p 10
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 179 180 177 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 254 262 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 289 290 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 375 376 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 448 456 446 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 624 632 <span type="species:ncbi:9606">patients</span>
We subsequently examined the distribution of PD-L1+ cells in HCC samples. Using confocal microscopy, we confirmed that PD-L1 protein was expressed mainly on CD68+ monocytes/Mphi (n = 10) and was only weakly expressed on other stromal and hepatoma cells (Fig. 1 D). Interestingly, only CD68+ cells in the peritumoral stroma showed marked expression of PD-L1, whereas most CD68+ cells in the cancer nests were weakly expressed or negative for PD-L1 (Fig. 1 D). Collectively, these data indicate that PD-L1 is selectively expressed on monocytes/Mphi in peritumoral stroma at levels that increase with progressive stages in HCC patients.
###end p 10
###begin title 11
Tumor environmental factors induce early transient expression of PD-L1 on monocytes
###end title 11
###begin p 12
###xml 174 175 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 621 629 617 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
We have recently shown that tumor microenvironments may co-opt the normal development of Mphi to dynamically educate the recruiting monocytes in different niches of a tumor (7). To investigate whether such mechanisms are also responsible for selective expression of PD-L1 on monocytes/Mphi in peritumoral stroma, we incubated normal blood monocytes with supernatants from cultures of hepatoma or normal liver cell lines. Exposure to 15% tumor culture supernatants (TSNs) from hepatoma (SK-Hep-1 and HepG2) cells induced rapid expression of PD-L1 on monocytes, reaching a maximum within 36 h and then gradually declining (Fig. 2 A). On day 7, TSN-exposed Mphi displayed significantly reduced expression of PD-L1. In contrast, supernatant from normal liver cells (LO2) had only a marginal effect on PD-L1 expression by monocytes/Mphi, even when used at a high concentration (30%).
###end p 12
###begin p 13
###xml 0 64 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumor environments regulated PD-L1 expression on monocytes/M&#966;.</bold>
Tumor environments regulated PD-L1 expression on monocytes/Mphi. (A) Monocytes were left untreated or cultured with the indicated supernatants for different times. (B and C) Monocytes were left untreated or cultured with supernatant from SK-Hep-1 cells (TSN) for the indicated times. (D) Monocytes were left untreated or pretreated for 1 h with the indicated blocking antibodies, Pep-1, or control peptide (Cpep), and were then incubated for 24 h with SK-Hep-1 TSN. In parallel, some untreated monocytes were incubated for 24 h with TSNs from mock or SiHAS2 cells. (E) Monocytes were incubated for 24 h with rhIL-10 or rhTNF-alpha at the indicated concentrations (ng/ml). The MFI of PD-L1 and expression of surface markers were determined by FACS, and the production of cytokines was assessed by ELISA. The histograms in B are representative of five separate experiments. Values given in A, C, D, and E represent the means +/- SE of four separate experiments. *, P < 0.05; and **, P < 0.01 indicate a significant difference from untreated TSN-exposed monocytes (D) or untreated monocytes (E).
###end p 13
###begin p 14
###xml 68 69 68 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 412 420 410 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 B</xref>
###xml 672 680 663 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 C</xref>
###xml 851 859 842 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 862 863 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
APCs are more susceptible to express PD-L1 when they are activated (4, 15); hence, we examined the activation status of TSN-exposed monocytes at their early or later differentiation stage. The results showed that the expression of HLA-DR, CD80, and CD86 was significantly up-regulated on monocytes after exposure to TSNs from hepatoma cells for 24 h, but was reduced on day 7 when the cells developed into Mphi (Fig. 2 B). Similar patterns of cytokine productions were obtained in TSN-exposed monocytes, including the accumulations of TNF-alpha, IL-10, IL-6, IL-12, and IL-1beta in the culture media at their early differentiation stage and a subsequent decline on day 7 (Fig. 2 C). Furthermore, comparison of the kinetics of PD-L1 expression and cytokine production in TSN-exposed monocytes revealed that cytokine profiles preceded PD-L1 expression (Fig. 2 A) (7). These findings suggest that TSN-induced activation of monocytes led to expression of PD-L1. The TSNs we used did not contain any measurable levels of TNF-alpha, IL-10, IL-1beta, or IL-12, except for a low concentration of IL-6 (227 +/- 53 pg/ml).
###end p 14
###begin title 15
Autocrine cytokines from activated monocytes induce expression of PD-L1
###end title 15
###begin p 16
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 404 412 400 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 659 667 651 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 846 854 834 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E</xref>
###xml 1117 1125 1101 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 E</xref>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 790 795 <span type="species:ncbi:9606">human</span>
###xml 1195 1200 <span type="species:ncbi:9606">human</span>
Cytokines derived from myeloid cells have previously been found to induce expression of PD-L1 in human tumor DCs (11). To ascertain whether autocrine cytokines from activated monocytes contribute to the expression of PD-L1, we used specific neutralizing antibodies to abolish the effects of TNF-alpha, IL-10, or IL-6. As expected, blocking IL-10 effectively inhibited the up-regulation of PD-L1 protein (Fig. 2 D). Interestingly, monocyte PD-L1 expression was also partially attenuated by the anti-TNF-alpha antibody, whereas it was not affected by treatment with a concentration of anti-IL-6 antibody that effectively neutralized IL-6 in the culture system (Fig. 2 D and ). To gain further support for roles of TNF-alpha and IL-10 in induction of PD-L1 on monocytes, we tested recombinant human (rh) cytokines in the culture system. As shown in Fig. 2 E, rhIL-10 induced significant expression of PD-L1 on monocytes in a dose-dependent manner. Although rhTNF-alpha alone, at concentrations up to 10 ng/ml, only had a marginal effect, it did synergistically increase the IL-10-mediated PD-L1 expression on monocytes (Fig. 2 E). These findings imply that IL-10 is involved in PD-L1 expression on human monocytes, and that effect can be potentiated by TNF-alpha.
###end p 16
###begin p 17
###xml 194 195 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 197 199 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 487 489 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 490 492 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 591 599 587 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 D</xref>
###xml 700 701 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 108 113 <span type="species:ncbi:9606">human</span>
We have recently observed that hyaluronan fragments constitute a common factor produced by several types of human tumors, including hepatoma, to stimulate the production of TNF-alpha and IL-10 (7, 16). Therefore, we examined whether hyaluronan fragments are involved in inducing expression of PD-L1 on monocytes. The results showed that the up-regulation of PD-L1 protein on TSN-exposed monocytes was significantly impaired both by adding a hyaluronan-specific blocking peptide (Pep-1) (16-18) and by reducing hyaluronan levels in TSNs via silencing of hyaluronan synthase 2 in tumor cells (Fig. 2 D), both of which have been shown to attenuate the release of TNF-alpha and IL-10 by these monocytes (7).
###end p 17
###begin title 18
###xml 94 102 <span type="species:ncbi:9606">patients</span>
PD-L1 expression and activation of monocytes/Mphi are correlated in peritumoral stroma in HCC patients
###end title 18
###begin p 19
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 462 466 462 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 556 567 554 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, A&#8211;C</xref>
###xml 598 602 596 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 606 610 604 608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 709 710 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 738 739 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 757 765 755 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 B</xref>
###xml 795 799 793 797 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 803 807 801 805 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 871 872 869 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 953 954 951 952 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 965 969 963 967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1012 1013 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1063 1071 1061 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 D</xref>
###xml 1245 1253 1241 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1273 1277 1269 1273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1376 1377 1372 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1415 1416 1411 1412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 322 330 <span type="species:ncbi:9606">patients</span>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
The results described above suggested that monocytes are activated by tumor environments to express PD-L1 protein during the early migration/differentiation stage. To test this, we examined the coexpression of PD-L1 and HLA-DR on monocytes freshly isolated from peripheral blood, tumor, or nontumor liver tissues from HCC patients (n = 28 for each group). Consistent with the results for PD-L1 expression, we observed a significantly increased percentage of CD14high cells with high HLA-DR intensity in the tumor tissues (63.3 +/- 3.7%; P < 0.001 for all; Fig. 3, A-C), and a higher ratio of HLA-DRhighCD14high cells in monocytes was found in tumor masses from advanced stage HCC patients (stages III and IV [n = 13] vs. stages I and II [n = 15]; P < 0.01; Fig. 3 B). Approximately 90% of HLA-DRhighCD14high cells from tumors also expressed substantial amounts of PD-L1 (n = 28). Moreover, significant correlations were found between the levels of PD-L1+ and HLA-DRhigh monocytes in all of the samples analyzed (n = 112; linear regression, r = 0.934; P < 0.0001; Fig. 3 D). The coexistence of HLA-DR and PD-L1 on monocytes/Mphi was further confirmed by examining expression of these proteins in serial sections of HCC tumor samples. As shown in Fig. 3 E, most of the HLA-DRhighCD68 cells were accumulated in the peritumoral stroma area, and they were also positive for PD-L1 (n = 15). Of note, most infiltrating CD8+ T cells were also located in the same area.
###end p 19
###begin p 20
###xml 0 111 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression pattern of PD-L1 was correlated with the activation pattern of monocytes/M&#966; in peritumoral stroma.</bold>
###xml 254 255 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 261 265 259 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 302 306 300 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 310 314 308 312 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 361 365 359 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 369 373 367 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 474 480 472 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1</xref>
###xml 826 827 822 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 838 842 834 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 984 985 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
###xml 974 982 <span type="species:ncbi:9606">patients</span>
Expression pattern of PD-L1 was correlated with the activation pattern of monocytes/Mphi in peritumoral stroma. (A-C) FACS analysis of PD-L1 and HLA-DR expression in fresh monocytes isolated from peripheral blood and tissues. Representative data on PD-L1+HLA-DRhigh monocytes (A), percentages of HLA-DRhighCD14high monocytes (B), and the MFI of HLA-DR in HLA-DRhighCD14high monocytes (C) are shown. The samples collected and the numbers of donors in A-C were the same as in Fig. 1. The data shown in A are representative dot plots of at least seven individuals from more than five independent experiments; B and C show the statistics analysis of these samples. The continuous and dashed horizontal bars in B represent median values. Results are expressed as means +/- SEM. (D) Positive correlations between the levels of PD-L1+ and HLA-DRhigh monocytes. The samples used in D were blood from healthy individuals, HCC patients, and paired nontumor and tumor tissues from HCC patients (n = 28 for each). (E) Adjacent sections of paraffin-embedded hepatoma samples stained with the indicated markers. The micrographs at higher magnification show the peritumoral stroma region (1) and a cancer nest (2). Significant difference compared with healthy blood is indicated (***, P < 0.0001). 1 out of 15 representative micrographs is shown in E. Bars, 150 microm.
###end p 20
###begin title 21
###xml 38 39 38 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 109 117 <span type="species:ncbi:9606">patients</span>
High infiltration of peritumoral PD-L1+ monocytes/Mphi is correlated with disease stage and poor survival of patients
###end title 21
###begin p 22
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 260 261 260 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 518 519 516 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 546 547 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 619 620 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 630 631 628 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 661 662 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 709 717 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 771 772 769 770 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 872 873 870 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 911 919 909 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 939 940 937 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1062 1063 1060 1061 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1259 1260 1257 1258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1333 1340 1331 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table I</xref>
###xml 1419 1420 1417 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 343 351 <span type="species:ncbi:9606">patients</span>
Based on our observation that in tissues from advanced stage HCC patients high levels of PD-L1 protein were expressed by CD68+ cells in peritumoral stroma, but not by those in intratumoral or nontumoral areas, we predicted that the presence of peritumoral CD68+ cells would have an adverse effect on survival. To test this assumption, 262 HCC patients received curative resection with follow-up data and were divided into two groups according to the median value of peritumoral stroma CD68 density (low, </=118 cells [n = 134]; high, >119 cells [n = 128]). There was a positive association between the densities of CD68+ and PD-L1+ cells in peritumoral stroma (n = 35; linear regression, r = 0.783; P < 0.01; Fig. 4 A), but striking negative associations between the CD68+ cell density in that area and overall survival (OS) and disease-free survival (DFS), respectively (n = 262; P < 0.01 for both OS and DFS; Fig. 4 B). In contrast, CD68+ cells in the nontumor area had no impact on the prognosis of either OS or DFS (unpublished data). Peritumoral stroma CD68+ cell density was also associated with tumor size (P = 0.032), tumor multiplicity (P = 0.003), and tumor node metastasis stage (P = 0.002; ). Multivariate analysis revealed that the number of CD68+ cells in peritumoral stroma was an independent prognostic factor of OS (Table I). These results suggest that an increase in numbers of peritumoral stroma CD68+ cells is correlated with progression of HCC and, therefore, might serve as an independent predictor of poor survival.
###end p 22
###begin p 23
Univariate and multivariate analyses of factors associated with survival and recurrence
###end p 23
###begin p 24
Cox proportional hazards regression model. Variables used in multivariate analysis were adopted by univariate analysis. The underlined terms represent statistical significance. AFP, alpha-fetoprotein; ALT, alanine aminotransferase; CI, confidence interval; HbsAg, hepatitis B surface antigen; HR, hazard ratio; NA, not adopted; TNM, tumor node metastasis.
###end p 24
###begin p 25
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 26 27 26 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 0 96 0 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Accumulation of PD-L1<sup>+</sup>CD68<sup>+</sup> cells in peritumoral stroma predicted poor survival in HCC patients.</bold>
###xml 596 597 590 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 658 659 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 694 695 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
Accumulation of PD-L1+CD68+ cells in peritumoral stroma predicted poor survival in HCC patients. (A) Adjacent sections of paraffin-embedded hepatoma samples stained with an anti-CD68 or an anti-PD-L1 antibody. Different levels of Mphi infiltration can be seen along the peritumoral region: I, none or slight; II, moderate; and III, strong. The dashed lines represent the edges of tumor, stroma, or normal tissues. Bars, 50 microm. (B) OS and DFS in 262 HCC patients in relation to CD68 density in peritumoral stroma. The patients were divided into two groups according to the median value of CD68+ Mphi density in peritumoral stroma: red lines, low density (n = 134); blue lines, high density (n = 128). Cumulative OS and DFS time were calculated by the Kaplan-Meier method and analyzed by the log-rank test.
###end p 25
###begin title 26
Monocyte-associated PD-L1 suppresses tumor-specific T cell immunity
###end title 26
###begin p 27
###xml 27 28 27 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 32 33 32 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 99 107 99 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 264 265 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 305 313 303 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 340 341 338 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 363 364 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 425 426 421 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 569 570 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 631 646 625 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, B and C</xref>
###xml 814 815 808 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1134 1136 1124 1126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 1138 1140 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 1216 1224 1202 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
The colocalization of PD-L1+CD68+ cells and CD8+ T cells in the peritumoral stroma of HCC tissues (Fig. 3 E) suggests that these monocytes/Mphi promote tumor progression by impairing T cell immunity. Therefore, our next objective was to determine the role of PD-L1+ tumor monocytes in T cell suppression. Fig. 5 A shows that most of the CD8+ T cells (78 +/- 15%; n = 15) in peritumoral stroma were in close contact with PD-L1+ cells. Interestingly, a significantly larger portion of the tumor-infiltrating cytotoxic cells expressed the PD-L1 receptor PD-1 (61 +/- 11%; n = 7; P < 0.001 compared with nontumor-infiltrating T cells; Fig. 5, B and C), which suggests that tumor monocytes may regulate T cell function via PD-L1 signals. To address that possibility, we purified tumor monocytes (>50% of them were PD-L1+) and autologous tumor-infiltrating T cells from HCC tissues, and then performed ELISPOT assays. The result showed that tumor T cells co-cultured with tumor monocytes exhibited an impaired production of IFN-gamma. Consistent with our hypothesis, blockade of PD-L1 by preincubation of tumor monocytes with the mAb MIH1 (19, 20) could markedly enhance the ability of tumor T cells to produce IFN-gamma (Fig. 5 D).
###end p 27
###begin p 28
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tumor-derived monocytes induced T cell suppression via PD-L1.</bold>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 502 503 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 492 500 <span type="species:ncbi:9606">patients</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 1117 1124 <span type="species:ncbi:9606">patient</span>
Tumor-derived monocytes induced T cell suppression via PD-L1. (A) Physical contact between PD-L1+ cells (red) and CD8+ cytotoxic T cells (green) in HCC peritumoral stroma. One out of five representative micrographs is shown in A. Bar, 20 microm. (B and C) Increased expression of PD-1 protein on the surface of tumor-infiltrating T cells from HCC patients. The samples used in B and C were fresh blood from healthy individuals and HCC patients, and paired nontumor and tumor tissues from HCC patients (n = 7 for each). The data shown in B are representative dot plots of seven patients from six independent experiments. The horizontal bars in C represent median values. (D) HCC-derived monocytes induced anergy of tumor T cells with reduced IFN-gamma production. Purified tumor T cells were left untreated (1), or were incubated for 20 h with autologous tumor monocytes supplemented with 25 microg/ml of autologous tumor mass lysate in the absence (2) or presence of 5 microg/ml of control (3) or anti-PD-L1 antibody (4). Thereafter, production of IFN-gamma was determined by ELISPOT. Three out of six representative patient samples are shown in D.
###end p 28
###begin p 29
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 488 489 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 697 703 693 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 854 860 850 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
To further elucidate the effect of PD-L1+ monocytes on T cell immunity, we generated one control T cell line stimulated with anti-CD3/CD28, and two types of tumor-reactive T cell lines with HepG2- and U937-loaded APCs, respectively (). Both tumor-reactive T cell lines can specifically inhibit the proliferation and exert their cytotoxicity against corresponding tumor cells, whereas the control T cell line hardly had any effect (Fig. S1, A and B). However, exposure to TSN-treated PD-L1+ monocytes for 24 h induced dysfunctional T cells that had a low cytotoxicity as well as impaired capacities for proliferation, expression of the activation marker CD25, and production of IL-2 and IFN-gamma (Fig. 6 and Fig. S1 C). Consistent with our hypothesis, blockade of PD-L1 significantly attenuated such T cell suppression mediated by TSN-treated monocytes (Fig. 6 and Fig. S1 C). Collectively, these findings show that PD-L1 contributes to tumor monocyte-mediated suppression in vitro.
###end p 29
###begin p 30
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TSN-exposed monocytes induced T cell suppression via PD-L1.</bold>
###xml 117 118 117 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 421 422 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
TSN-exposed monocytes induced T cell suppression via PD-L1. Autologous monocytes (MO) or TSN-treated monocytes (PD-L1+ MO) were pretreated with 10 microg/ml mitomycin C for 30 min and were then washed and incubated with tumor-specific T cells (1:10) in the presence or absence of 5 microg/ml anti-PD-L1 or control antibody, as described in Materials and methods. The expression of CD25 on (A) T cells, (B) perforin in CD8+ T cells, and (C) intracellular staining of IFN-gamma were determined by FACS, and (D) the secretion of cytokines and proliferation of T cells were determined by ELISA and BrdU assay, respectively. The results shown are representative of at least four separate experiments and are expressed as means +/- SEM. Significant differences compared with normal monocytes are indicated (*, P < 0.05; and **, P < 0.01).
###end p 30
###begin title 31
Blockade of monocyte-associated PD-L1 improves tumor-specific T cell immunity
###end title 31
###begin p 32
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 455 456 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 500 501 500 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 798 799 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 864 870 864 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 370 374 <span type="species:ncbi:10090">mice</span>
###xml 404 408 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:10090">mice</span>
###xml 804 808 <span type="species:ncbi:10090">mice</span>
To test the effect of monocyte PD-L1 on tumor-specific T cell immunity in vivo, we treated TSN-exposed PD-L1+ monocytes with PD-L1 blocking or control antibody and then injected them together with autologous tumor-specific T cells into our established human nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice bearing HepG2-derived hepatoma. As expected, mice without T cell transfusions, mice treated with tumor-specific T cells plus PD-L1+ monocytes or control antibody-treated PD-L1+ monocytes, showed progressive tumor growth. Supporting our hypothesis that tumor monocyte PD-L1 signals are immunopathological in vivo, mice treated with tumor-specific T cells plus PD-L1 blocking antibody-treated monocytes showed reduced tumor volumes at each measurement time point from day 8 (n = 4 mice per group; *, P < 0.05 compared with control antibody; Fig. 7). These data indicate that tumor monocytes defeat tumor-specific T cell immunity in vivo via PD-L1 signals and thereby contribute to tumor growth.
###end p 32
###begin p 33
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blockade of PD-L1 improved monocyte-mediated T cell activation in vivo.</bold>
###xml 656 657 600 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 157 161 <span type="species:ncbi:10090">Mice</span>
###xml 181 186 <span type="species:ncbi:9606">human</span>
###xml 691 695 <span type="species:ncbi:10090">mice</span>
Blockade of PD-L1 improved monocyte-mediated T cell activation in vivo. (A) Blocking PD-L1 in TSN-conditioned monocytes results in tumor regression in vivo. Mice were injected with human HepG2 cells, as described in Materials and methods. The control animals (black triangle) received no further injections. The experimental treatments entailed injections with tumor-specific T cells in combination with untreated monocytes (square) or TSN-exposed monocytes (*), or TSN-exposed monocytes pretreated with an anti-PD-L1 antibody (triangle up) or a control antibody (blacksquare, square, filled). The illustrated data represent means +/- SD of tumor volumes (n = 8 tumors in each group of four mice). The day of T cell injection was counted as day 0. The results shown in A are representative of three separate experiments and are expressed as means +/- SEM. *, P < 0.05 compared with control antibody. CTL, tumor-specific T cells; MO, monocytes; TMO, TSN-exposed monocytes. (B) The tumors were excised and photographed 21 d after injecting the cells. One out of three separate experiments is shown in B.
###end p 33
###begin title 34
DISCUSSION
###end title 34
###begin p 35
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
Much research has been focused on tumor-mediated immunosuppression over the past decade (4, 21). However, in spite of the generalized immunosuppressive status in cancer patients, many malignancies arise at sites of chronic inflammation, and inflammatory mediators are often produced in tumors (22-24). The present study demonstrates that the activated monocytes in a tumor microenvironment express PD-L1 (B7-H1) molecules to suppress tumor-specific T cell function, which may represent a novel link between proinflammatory response and immune tolerance in the tumor milieu.
###end p 35
###begin p 36
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 695 701 695 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 1406 1407 1397 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1413 1414 1404 1405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1510 1511 1501 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 1301 1309 <span type="species:ncbi:9606">patients</span>
Human tumor tissues can be anatomically classified into areas of intratumoral and peritumoral stroma, each with distinct compositions and functional properties (5, 7, 24, 25). Intratumoral environments usually contain abundant immunosuppressive molecules and cells to inhibit the T cell responses and create conditions that are conducive to tumor growth (21, 26-28). In contrast, the stromal areas in most tumors contain a significant amount of leukocyte infiltrate, which was long assumed to represent the host response to the malignancy. In the current study, we observed that monocytes in the peritumoral stroma had an activated phenotype with increased expression of HLA-DR, CD80, and CD86 (Fig. 3 and not depicted). Data from an in vitro study showed that such tumor-activated monocytes produced significant levels of proinflammatory cytokines, including IL-1beta, IL-12, and TNF-alpha. However, these activated APCs were unable to stimulate effective antitumor T cell responses, and instead they suppressed the T cell immunity both in vitro and in vivo, which suggests that such monocytes can actually benefit tumor progression. This notion is supported by our finding that the density of monocytes/Mphi in peritumoral stroma was correlated with advanced disease stages and poor survival in HCC patients. Consistent with our results, other investigators have recently reported that the increased CD68+HLA-DR+ cells in peritumoral liver tissues are positively associated with metastatic potential in HCC (5).
###end p 36
###begin p 37
###xml 113 114 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 116 118 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 350 351 346 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 609 610 605 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1044 1045 1040 1041 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1056 1060 1052 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">high</sup>
###xml 1433 1434 1429 1430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 714 719 <span type="species:ncbi:9606">human</span>
###xml 1665 1673 <span type="species:ncbi:9606">patients</span>
Mphi are versatile, plastic cells that can respond to environmental signals through diverse functional programs (6, 29). We have recently shown that tumors dynamically regulate recruiting monocytes at distinct sites, which leads to transient activation of monocytes in peritumoral stroma and subsequent formation of suppressive Mphi in cancer nests (7). The present study provided evidence that a fraction of these activated monocytes express PD-L1, and that those cells significantly inhibit tumor-specific T cell proliferation, cytokine production, and cytotoxic potential in vitro. We also found that PD-L1+ monocytes inhibited tumor-specific immunity in vivo and fostered tumor growth in NOD/SCID mice bearing human tumors. Several of our observations support the notion that tumor monocyte PD-L1 signals contribute to immunopathology. First, tumor-activated monocytes in our experiments strongly expressed PD-L1 molecules with kinetics similar to their activation status, and significant correlations were found between the levels of PD-L1+ and HLA-DRhigh on tumor-infiltrating monocytes. Second, these PD-L1-expressing monocytes effectively suppressed the tumor-specific T cell immunity, and that effect was attenuated by blocking PD-L1 on these monocytes. Third, expression of the PD-L1 receptor PD-1 was significantly increased on tumor-infiltrating T cells, and many of those cells were in close contact with activated PD-L1+ monocytes in peritumoral stroma. Fourth, expression of PD-L1 on tumor-infiltrating monocytes was increased with HCC progression, and greater intensity of such protein was associated with high mortality and reduced survival in the patients. Therefore, expression of PD-L1 on activated monocytes may represent a novel mechanism that represses antitumor T cell immunity.
###end p 37
###begin p 38
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 898 899 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 923 931 907 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 A</xref>
###xml 1503 1505 1472 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 1507 1509 1476 1478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 163 168 <span type="species:ncbi:10090">mouse</span>
###xml 371 376 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
PD-L1 is a cell-surface glycoprotein belonging to the B7 family of cosignaling molecules with a profound regulatory effect on T cell responses (30-32). Studies in mouse models have revealed that expression of PD-L1 helped dormant tumor cells to evade cytotoxic T cell responses (33, 34). Although expression of PD-L1 protein is often found on activated cells and various human carcinomas, the regulatory mechanisms of human PD-L1 remain to be defined. We found that autocrine TNF-alpha and IL-10, but not IFN-gamma, released from activated monocytes, stimulated monocyte PD-L1 expression. Furthermore, in vitro study using recombinant TNF-alpha and IL-10 indicated that IL-10 was essential for PD-L1 induction and that proinflammatory TNF-alpha acted synergistically with antiinflammatory IL-10 to enhance PD-L1 expression on monocytes. Moreover, comparison of the kinetics of cytokine production (7) and PD-L1 expression (Fig. 2 A) in TSN-treated monocytes revealed that accumulation of TNF-alpha and IL-10 preceded the up-regulation of PD-L1. Such sequential cytokine production and PD-L1 expression on TSN-activated monocytes may reflect a novel immune-editing mechanism by which tumors render activated monocytes to perform a suppressive role by stimulating PD-L1 expression. This hypothesis is compatible with previous studies showing that the proinflammatory cytokines IL-1beta or TNF-alpha can significantly enhance IFN-gamma-dependent indoleamine 2,3-dioxygenase expression on epithelial cells (35, 36).
###end p 38
###begin p 39
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 292 293 290 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 388 390 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 599 601 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 796 798 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 800 802 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 782 787 <span type="species:ncbi:9606">human</span>
In addition to PD-L1, another member of the B7 family, B7-H4, is also selectively expressed by various cellular components in the tumor microenvironment (4, 28). High levels of B7-H4 have been detected on a fraction of tumor-associated Mphi in patients with ovarian carcinoma, and these B7-H4+ Mphi were found to inhibit tumor-specific T cell effector function both in vitro and in vivo (37). Moreover, regulatory T cells can trigger production of IL-10 by APCs, which in turn stimulates such cells to express B7-H4 in an autocrine manner and renders them immunosuppressive via the B7-H4 molecules (38). Therefore, manipulating the expression of and signaling through these molecules may open new avenues for developing novel immune-based therapies to enhance antitumor immunity in human cancer (39, 40).
###end p 39
###begin p 40
Emerging evidence indicates that it is not inflammation per se but inflammatory "context" that determines the ability of proinflammatory factors to facilitate or prevent tumor growth. Our results suggest that there is fine-tuned collaborative action between immune activation and immunosuppression in tumor microenvironments. Soluble factors derived from cancer cells can trigger transient activation of newly recruited monocytes in the peritumoral stroma area, and thereby induce the monocytes to produce significant amount of cytokines, including TNF-alpha and IL-10, which in turn leads to the expression of PD-L1 (B7-H1) protein on their surface and ultimately impairs the antitumor T cell immunity. These findings provide important new insight into the significance about how activated monocytes in tumors may perform a suppressive role by stimulating PD-L1 (B7-H1) expression, which would be helpful for the rational design of novel immune-based anticancer therapies.
###end p 40
###begin title 41
MATERIALS AND METHODS
###end title 41
###begin title 42

###end title 42
###begin title 43
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and specimens.
###end title 43
###begin p 44
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
###xml 709 717 <span type="species:ncbi:9606">patients</span>
Tumor or peripheral blood samples were obtained from 312 untreated patients with pathologically confirmed HCC at the Sun Yat-Sen University Cancer Center. Of these, 262 patients who underwent curative resection between 1999 and 2004 (designated Group 1) had complete follow-up data, and they were further enrolled for analysis of OS and DFS. Clinical stages were classified according to the International Union against Cancer. Blood samples from 28 patients as well as fresh tumor and nontumor (at least 3 cm away from the tumor site) tissues from 28 patients (Group 2) were used for the isolation of peripheral leukocytes, and tumor- and nontumor-infiltrating leukocytes. The clinical characteristics of all patients are summarized in .
###end p 44
###begin p 45
###xml 152 169 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 171 188 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 190 193 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Control blood samples were obtained from 28 healthy blood donors attending the Guangzhou Blood Center, all of whom were negative for antibodies against hepatitis C virus, hepatitis B virus, HIV, and syphilis. All samples were anonymously coded in accordance with local ethical guidelines (as stipulated by the Declaration of Helsinki), and written informed consent was obtained and the protocol was approved by the Review Board of Sun Yat-Sen University Cancer Center.
###end p 45
###begin title 46
Isolation of mononuclear cells from peripheral blood and tissues.
###end title 46
###begin p 47
###xml 79 80 79 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
###xml 211 212 211 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Peripheral leukocytes were isolated by Ficoll density gradient centrifugation (7). Fresh tumor- and nontumor-infiltrating leukocytes were obtained as previously described (41). In short, liver biopsy specimens (n = 28) were cut into small pieces and digested in RPMI 1640 supplemented with 0.05% collagenase IV (Sigma-Aldrich), 0.002% DNase I (Roche), and 20% FCS (HyClone Laboratories) at 37degreesC for 20 min. Dissociated cells were filtered through a 150-microm mesh and separated by Ficoll centrifugation. The mononuclear cells were washed and resuspended in medium supplemented with 1% heat-inactivated FCS for FACS analysis.
###end p 47
###begin title 48
ELISPOT assay.
###end title 48
###begin p 49
###xml 478 479 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 321 326 <span type="species:ncbi:9606">human</span>
###xml 727 732 <span type="species:ncbi:9606">human</span>
###xml 794 805 <span type="species:ncbi:3704">horseradish</span>
Tumor monocytes and T cells were purified from HCC-infiltrating leukocytes in a MACS column purification system (Miltenyi Biotec). ELISPOT assays were performed using a commercial set (BD) according to the manufacturer's instructions. In brief, 96-well nitrocellulose plates (Millipore) were coated with 5 microg/ml anti-human IFN-gamma capture antibody at 4degreesC overnight. The wells were then washed and blocked for 2 h at room temperature with 10% FBS-RPMI 1640 medium. 105 purified tumor T cells were left untreated or cultured with autologous tumor monocytes (5:1) in the presence of 25 microg/ml of tumor mass lysates and incubated for 20 h. After wash, the plates were incubated with 2 microg/ml of biotinylated anti-human IFN-gamma detection antibody and developed with streptavidin-horseradish peroxidase, followed by the addition of 3-amino-9-ethylcarbazole substrate reagent.
###end p 49
###begin title 50
Flow cytometry.
###end title 50
###begin p 51
Peripheral blood leukocytes and tumor- and nontumor-infiltrating leukocytes were stained with fluorochrome-conjugated mAbs against PD-L1, CD14, CD80, CD86, or HLA-DR, or control antibodies (BD or eBioscience) according to the manufacturer's instructions, and they were subsequently analyzed by multicolor flow cytometry.
###end p 51
###begin title 52
Cell lines and preparation of TSNs.
###end title 52
###begin p 53
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 566 567 566 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human hepatoma (SK-Hep-1 and HepG2) cell lines were obtained from American Type Culture Collection; normal liver (LO2) cells were obtained from the Institute of Biochemistry and Cell Biology at the Chinese Academy of Sciences; and the stable hyaluronan synthase 2-knockdown SK-Hep-1 clones (SiHAS2) and the mock transfectants were established in our previous study (7, 42). All cells were tested for mycoplasma contamination using a single-step PCR method (43), and they were maintained in DMEM supplemented with 10% FCS. TSNs were prepared as previously described (7, 16).
###end p 53
###begin title 54
Regulation of PD-L1 expression.
###end title 54
###begin p 55
Fresh blood monocytes were cultured for the indicated times with TSNs or different concentrations of rhIL-10 and rhTNF-alpha (R & D Systems). In some experiments, before exposure to TSNs, the cells were pretreated with neutralizing mAbs against 20 microg/ml IL-6, 10 microg/ml IL-10, or 1 microg/ml TNF-alpha (R & D Systems), or with hyaluronan-blocking peptide (200 microg/ml pep-1; GL Biochem). Cells were subject to FACS analysis to detect surface PD-L1 protein, and the levels of TNF-alpha, IL-12p70, IL-1beta, IL-6, and IL-10 in culture supernatants were detected by ELISA (eBioscience).
###end p 55
###begin title 56
Immunohistochemistry and immunofluorescence.
###end title 56
###begin p 57
###xml 154 155 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 974 976 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 978 980 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 200 205 <span type="species:ncbi:9606">human</span>
###xml 488 494 <span type="species:ncbi:9986">rabbit</span>
###xml 500 505 <span type="species:ncbi:9606">human</span>
###xml 514 519 <span type="species:ncbi:10090">mouse</span>
###xml 525 530 <span type="species:ncbi:9606">human</span>
###xml 541 547 <span type="species:ncbi:9986">rabbit</span>
###xml 553 558 <span type="species:ncbi:9606">human</span>
###xml 601 606 <span type="species:ncbi:10090">mouse</span>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 672 676 <span type="species:ncbi:9925">goat</span>
###xml 682 687 <span type="species:ncbi:10090">mouse</span>
###xml 731 735 <span type="species:ncbi:9925">goat</span>
###xml 741 747 <span type="species:ncbi:9986">rabbit</span>
Paraffin-embedded and formalin-fixed samples were cut into 5-microm sections, which were then processed for immunohistochemistry as previously described (7). After incubation with an antibody against human CD8 (Thermo Fisher Scientific), CD68 (Dako), HLA-DR (R&D Systems), or PD-L1 (MIH1; eBioscience), the adjacent sections were stained with diaminobenzidine or 3-amino-9-ethylcarbazole in an Envision System (Dako). For immunofluorescence analysis, tissues were stained with polyclonal rabbit anti-human CD8 and mouse anti-human PD-L1, or rabbit anti-human CD68 (Santa Cruz Biotechnology, Inc.) and mouse anti-human PD-L1, followed by Alexa Fluor 488- or 568-conjugated goat anti-mouse IgG and Alexa Fluor 568- or 488-conjugated goat anti-rabbit IgG (Invitrogen). Positive cells were quantified using ImagePro Plus software (Media Cybernetics) and expressed as the mean of the percentage of positive cells +/- SD in 10 high-powered fields detected by confocal microscopy (16, 37).
###end p 57
###begin title 58
Evaluation of immunohistochemical variables.
###end title 58
###begin p 59
###xml 308 309 308 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 418 419 416 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Analysis was performed by two independent observers who were blinded to the clinical outcome. At low power (x100), the tissue sections were screened using an inverted research microscope (model DM IRB; Leica), and the five most representative fields were selected. Thereafter, to evaluate the density of CD68+ Mphi, the respective areas of peritumoral stroma were measured at x400 magnification, and the nucleated CD68+ Mphi in each area were counted and expressed as the number of cells per field.
###end p 59
###begin title 60
In vitro tumor-specific T cell immunosuppression.
###end title 60
###begin p 61
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 983 988 <span type="species:ncbi:9606">human</span>
Monocyte-derived DCs were incubated with irradiated apoptotic HepG2 or U937 cells at a 1:5 ratio for 24 h. Autologous blood CD3 T cells (2 x 105 cells/well in 96-well plates; Pan T cell kit; Miltenyi Biotec) were activated by incubation with those tumor-loaded DCs (2 x 104 cells/well) in the presence of 10 U/ml IL-2 (11, 37) and 10 ng/ml IL-7 for 2 wk. Thereafter, a second stimulation was performed by further incubation with tumor-loaded DCs for another 2 wk to generate tumor-specific T cells. The control T cell lines were generated via polyclonal stimulations (2.5 microg/ml anti-CD3 and -CD28). The specificity of T cells was examined in Fig. S1 (A and B). Autologous or TSN-treated monocytes were pretreated with 10 microg/ml mitomycin C (Sigma-Aldrich) for 30 min, washed twice, and co-cultured for 24 h with polyclonal-stimulated (0.5 microg/ml anti-CD3 and 0.1 microg/ml anti-CD28) tumor-specific T cells at a ratio of 1:10 in the presence or absence of 5 microg/ml anti-human PD-L1 antibody, and BrdU (Roche) was present during the final 5 h. The production of cytokines and proliferation of cells were detected by ELISA. In some experiments, 10 microg/ml brefeldin A (Sigma-Aldrich) was added to the culture for the final 5 h, and the intracellular cytokines were determined by FACS.
###end p 61
###begin title 62
In vivo tumor regression assay.
###end title 62
###begin p 63
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 269 270 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 728 730 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 222 226 <span type="species:ncbi:10090">mice</span>
###xml 255 260 <span type="species:ncbi:10090">mouse</span>
Animal protocols were approved by the Review Board of Sun Yat-Sen University Cancer Center. 106 hepatoma cells (HepG2) in 100 microl of buffered saline were subcutaneously injected into the dorsal tissues of male NOD/SCID mice (5-7 wk old, two tumors per mouse). 5 x 106 tumor-specific T cells were conditioned with monocytes or TSN-treated monocytes in the presence or absence of PD-L1 antibody, as described in the previous section, and were subsequently injected into the peritoneum in 100 microl of buffered saline on day 7 after inoculation. Tumor size was measured twice weekly by two independent observers using calipers fitted with a vernier scale. Tumor volume was calculated based on three perpendicular measurements (37).
###end p 63
###begin title 64
Statistical analysis.
###end title 64
###begin p 65
###xml 131 132 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Results are expressed as means +/- SEM. The statistical significance of differences between groups was determined by the Student's t test. Correlations between parameters were assessed using the Pearson correlation analysis and linear regression analysis, as appropriate. Cumulative survival time was calculated by the Kaplan-Meier method, and survival was measured in months from resection to recurrence or the last review. The log-rank test was applied to compare the groups. Multivariate analysis of prognostic factors for OS and DFS were performed using the Cox proportional hazards model. SPSS statistical software (version 13.0) was used for all statistical analyses. All data were analyzed using two-tailed tests unless otherwise specified, and P < 0.05 was considered statistically significant.
###end p 65
###begin title 66
Online supplemental material.
###end title 66
###begin p 67
###xml 72 73 72 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
Fig. S1 shows the regulation of T cell cytotoxicity by TSN-exposed PD-L1+ monocytes. Table S1 summarizes the blocking effects of IL-10, TNF-alpha, and IL-6 in the co-culture system by use of specific mAbs. Table S2 shows the association of peritumoral stroma CD68 cells with clinicopathological characteristics. Table S3 lists the clinical characteristics of 312 patients with HCC. Online supplemental material is available at .
###end p 67
###begin title 68
Supplementary Material
###end title 68
###begin title 69
[Supplemental Material Index]
###end title 69
###begin p 70
We thank P. Odman for linguistic revision of the manuscript and G. Zhang for help with confocal microscopy.
###end p 70
###begin p 71
This work was supported by the Outstanding Young Scientist Fund and project grants from the National Natural Science Foundation of China (30425025, 30672388, and 30730086), the "973" Program (2004CB518801), and the Ministry of Health of China (2008ZX10002-019).
###end p 71
###begin p 72
The authors declare no competing financial interests.
###end p 72
###begin article-title 73
Friends or foes - bipolar effects of the tumor stroma in cancer.
###end article-title 73
###begin article-title 74
Tumor stroma and regulation of cancer development.
###end article-title 74
###begin article-title 75
Tumor stroma as a target in cancer.
###end article-title 75
###begin article-title 76
Inhibitory B7-family molecules in the tumor microenvironment.
###end article-title 76
###begin article-title 77
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.
###end article-title 77
###begin article-title 78
Monocyte and macrophage heterogeneity.
###end article-title 78
###begin article-title 79
Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes.
###end article-title 79
###begin article-title 80
Distinct role of macrophages in different tumor microenvironments.
###end article-title 80
###begin article-title 81
Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection.
###end article-title 81
###begin article-title 82
The B7 family and cancer therapy: costimulation and coinhibition.
###end article-title 82
###begin article-title 83
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
###end article-title 83
###begin article-title 84
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
###end article-title 84
###begin article-title 85
Significance of B7-H1 overexpression in kidney cancer.
###end article-title 85
###begin article-title 86
Hepatocellular carcinoma.
###end article-title 86
###begin article-title 87
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
###end article-title 87
###begin article-title 88
Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways.
###end article-title 88
###begin article-title 89
Regulation of lung injury and repair by Toll-like receptors and hyaluronan.
###end article-title 89
###begin article-title 90
Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking.
###end article-title 90
###begin article-title 91
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells.
###end article-title 91
###begin article-title 92
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
###end article-title 92
###begin article-title 93
Immunosuppressive strategies that are mediated by tumor cells.
###end article-title 93
###begin article-title 94
Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer.
###end article-title 94
###begin article-title 95
Inflammation and cancer.
###end article-title 95
###begin article-title 96
Inflammation and necrosis promote tumour growth.
###end article-title 96
###begin article-title 97
Stromal gene expression predicts clinical outcome in breast cancer.
###end article-title 97
###begin article-title 98
###xml 121 129 <span type="species:ncbi:9606">patients</span>
The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma.
###end article-title 98
###begin article-title 99
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
###end article-title 99
###begin article-title 100
Immunosuppressive networks in the tumour environment and their therapeutic relevance.
###end article-title 100
###begin article-title 101
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.
###end article-title 101
###begin article-title 102
PD-1 and its ligands in tolerance and immunity.
###end article-title 102
###begin article-title 103
The B7 family revisited.
###end article-title 103
###begin article-title 104
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.
###end article-title 104
###begin article-title 105
###xml 80 97 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 103 109 <span type="species:ncbi:10090">murine</span>
Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model.
###end article-title 105
###begin article-title 106
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability.
###end article-title 106
###begin article-title 107
IDO expression by dendritic cells: tolerance and tryptophan catabolism.
###end article-title 107
###begin article-title 108
Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells.
###end article-title 108
###begin article-title 109
###xml 73 78 <span type="species:ncbi:9606">human</span>
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
###end article-title 109
###begin article-title 110
Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells.
###end article-title 110
###begin article-title 111
Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.
###end article-title 111
###begin article-title 112
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
###end article-title 112
###begin article-title 113
Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
###end article-title 113
###begin article-title 114
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells.
###end article-title 114
###begin article-title 115
Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction.
###end article-title 115
###begin p 116
###xml 232 237 <span type="species:ncbi:9606">human</span>
Abbreviations used: DFS, disease-free survival; HCC, hepatocellular carcinoma; MFI, mean fluorescence intensity; Mphi, macrophages; NOD/SCID, nonobese diabetic/severe combined immunodeficiency; OS, overall survival; rh, recombinant human; TSN, tumor culture supernatant.
###end p 116

